Haleon PLC Sponsored ADR (NYSE:HLN) Shares Bought by Ballentine Partners LLC

Ballentine Partners LLC raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 9.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,620 shares of the company’s stock after buying an additional 2,659 shares during the period. Ballentine Partners LLC’s holdings in Haleon were worth $305,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its holdings in Haleon by 3.7% in the 4th quarter. FMR LLC now owns 108,827,814 shares of the company’s stock worth $1,038,217,000 after buying an additional 3,909,545 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after buying an additional 6,175,835 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Haleon by 0.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,630,307 shares of the company’s stock worth $72,793,000 after buying an additional 58,444 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Haleon by 18.3% in the 4th quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company’s stock worth $57,382,000 after buying an additional 930,701 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Haleon by 27.7% in the 4th quarter. Northern Trust Corp now owns 5,412,542 shares of the company’s stock worth $51,636,000 after buying an additional 1,172,931 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HLN shares. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a report on Saturday. BNP Paribas Exane upgraded Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 target price on the stock in a report on Tuesday, May 27th. Barclays restated an “overweight” rating on shares of Haleon in a report on Tuesday, May 6th. Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 target price on the stock in a report on Friday, May 9th. Finally, BNP Paribas upgraded Haleon to a “strong-buy” rating in a report on Tuesday, May 27th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Down 1.7%

HLN stock opened at $9.73 on Wednesday. The firm has a market cap of $43.71 billion, a PE ratio of 24.95, a PEG ratio of 2.86 and a beta of 0.25. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.78 and a current ratio of 0.98. The firm’s 50 day moving average price is $10.66 and its 200-day moving average price is $10.16. Haleon PLC Sponsored ADR has a one year low of $8.68 and a one year high of $11.42.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.